GlassScriptPhysician profile
Bridget E Przybyla
NPI 1326387788
$4,325.29
in general payments reported to CMS, 2019-2025
21 companies · $614 in 2025
The $614 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,049 · 2022: $885 · 2023: $1,102 · 2024: $676 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,391.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,305.98 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $946.85 | 2021-2025 | |
| Uswm, LLC | $440.36 | 2021-2024 | Lucemyra, Zimhi |
| Orexo US, INC. | $249.31 | 2021-2025 | Zubsolv |
| Neurocrine Biosciences, INC. | $208.23 | 2021-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $207.35 | 2022-2024 | Quviviq |
| Indivior INC. | $176.97 | 2022-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $146.48 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $125.56 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.54 | 2022-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $79.68 | 2021 | |
| Exact Sciences Corporation | $53.10 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.00 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $44.60 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $40.22 | 2021-2025 | Otezla, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.21 | 2022-2023 | Breztri |
| Pfizer INC. | $32.24 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $21.21 | 2023 | |
| Braeburn INC. | $20.88 | 2025 | Brixadi |
| Sumitomo Pharma America, INC. | $20.21 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Przybyla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.